WO2019151602A1 - Composition pour la formation d'une couche de peau artificielle à l'aide de nanoparticules hydrophobes, et procédé de préparation d'une couche de peau artificielle l'utilisant - Google Patents

Composition pour la formation d'une couche de peau artificielle à l'aide de nanoparticules hydrophobes, et procédé de préparation d'une couche de peau artificielle l'utilisant Download PDF

Info

Publication number
WO2019151602A1
WO2019151602A1 PCT/KR2018/010627 KR2018010627W WO2019151602A1 WO 2019151602 A1 WO2019151602 A1 WO 2019151602A1 KR 2018010627 W KR2018010627 W KR 2018010627W WO 2019151602 A1 WO2019151602 A1 WO 2019151602A1
Authority
WO
WIPO (PCT)
Prior art keywords
artificial skin
nanoparticles
platinum catalyst
platinum
composition
Prior art date
Application number
PCT/KR2018/010627
Other languages
English (en)
Korean (ko)
Inventor
이정건
김용호
배도현
주정옥
Original Assignee
주식회사 에스스킨
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 에스스킨, 성균관대학교산학협력단 filed Critical 주식회사 에스스킨
Publication of WO2019151602A1 publication Critical patent/WO2019151602A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

  • the present application relates to a composition for forming an artificial skin film using hydrophobic nanoparticles and a method for producing an artificial skin film using the composition for forming an artificial skin film.
  • Artificial skin is a biomaterial for skin replacement for regenerating skin tissue damaged by severe burns, trauma and skin diseases. Such artificial skin is a material harmless to the human body, and has a function of protecting the wound by forming another layer having elasticity and softness on the skin.
  • research has been conducted focusing on the development of artificial skin for skin coating to prevent only the influx of harmful substances from outside to protect burns and trauma wounds.
  • the present application is to provide a composition for forming an artificial skin film using hydrophobic nanoparticles and a method for preparing an artificial skin film using the composition for forming an artificial skin film.
  • a first aspect of the present disclosure provides an agent comprising an organopolysiloxane unit; And, it provides a composition for forming an artificial skin film comprising a nanoparticle coated with a hydrophobic material and a second agent comprising a platinum catalyst supported on the nanoparticles.
  • the second aspect of the present application provides a kit for forming an artificial skin film, comprising the composition for forming an artificial skin film according to the first aspect of the present application.
  • the third aspect of the present application is applied to the skin by applying a first agent comprising an organopolysiloxane unit, and a second agent comprising nanoparticles coated with a hydrophobic material and a platinum catalyst supported on the nanoparticles to the skin
  • a first agent comprising an organopolysiloxane unit and a second agent comprising nanoparticles coated with a hydrophobic material and a platinum catalyst supported on the nanoparticles
  • an artificial skin membrane comprising a polysiloxane polymer
  • artificial skin comprising a polysiloxane polymer by applying a second agent comprising a nanoparticle coated with a hydrophobic material and a platinum catalyst supported on the nanoparticle, and applying a first agent comprising an organopolysiloxane unit to the skin.
  • a method of making an artificial skin film the method comprising forming a film.
  • the composition for forming an artificial skin film By forming the artificial skin film by the composition for forming an artificial skin film according to an embodiment of the present application, while the wrinkles of the skin can be improved in a short time (for example, within about 5 minutes), while the elasticity, such as skin, moisture of the skin The protective effect can be maintained.
  • Composition for forming an artificial skin film according to an embodiment of the present application while maintaining the stability for a long time storage, it can ensure the safety for the skin.
  • FIG. 1 1, in one embodiment of the present application, is a schematic diagram showing a process of forming a skin film using a composition for forming an artificial skin film comprising a nano-catalyst utilizing hydrophobic nanoparticles.
  • Figure 2 in one embodiment of the present application, is a manufacturing flowchart of the artificial skin film using the composition for forming a synthetic skin film.
  • FIG. 3 is a photograph of non-coated nanoparticles (hydrophilic), and hydrophobic silica nanoparticles coated with PDMS according to an embodiment of the present application in water.
  • FIG. 4 is a photograph comparing and measuring contact angles of (a) uncoated silica nanoparticles, and (b) hydrophobic silica nanoparticles coated with PDMS according to an embodiment of the present application.
  • Figure 5 is a photograph comparing and measuring the contact angle of (a) titanium oxide nanoparticles not coated, and (b) hydrophobic titanium oxide nanoparticles coated with PDMS according to an embodiment of the present application.
  • FIG. 6 is a photo (a) of uncoated silica nanoparticles (hydrophilic), and hydrophobic silica nanoparticles coated with PDMS according to an embodiment of the present application, respectively, with a platinum catalyst, and centrifugation of (a). It is photograph (b) after separation.
  • FIG. 7 is a photograph of artificial skin film formation using only (a) platinum catalyst, and (b) artificial skin film formation using nanoparticles to which platinum catalyst is adsorbed according to an embodiment of the present application.
  • 8A to 8F are graphs showing the difference in surface potential before and after adsorption of a platinum catalyst using zeta-potential in one embodiment of the present application.
  • FIG. 9 is a graph showing the adsorption rate according to the ultrasonic reaction time of the platinum catalyst and nanoparticles of the composition for forming an artificial skin film according to one embodiment of the present application.
  • FIG. 11 is a schematic diagram showing a lactate dehydrogenase (LDH) analysis method in an example of the present application.
  • LDH lactate dehydrogenase
  • FIG. 12 is a graph showing the cytotoxicity of the platinum catalyst alone and the platinum catalyst adsorbed on the nanoparticles according to the example of the present application according to the platinum catalyst concentration.
  • FIG. 13 is a graph illustrating measurement results (Ra) according to surface roughness parameters when evaluating eye wrinkle coverage of a composition for forming an artificial skin film according to one embodiment of the present application.
  • FIG. 14 is a graph illustrating measurement results (Rmax) according to surface roughness parameters when evaluating eye wrinkle coverage of a composition for forming an artificial skin film according to one embodiment of the present application.
  • FIG. 15 is a graph illustrating a standard deviation measurement result before and immediately after application of skin in evaluating makeup sustainability of a composition for forming an artificial skin film according to one embodiment of the present application.
  • Figure 16 in one embodiment of the present application, a graph showing the measurement results of the standard deviation before and after the application of the skin at the time of makeup makeup evaluation of the composition for forming an artificial skin film after 3 hours.
  • the term "combination (s) thereof" included in the expression of a makushi form refers to one or more mixtures or combinations selected from the group consisting of components described in the expression of makushi form, It means to include one or more selected from the group consisting of the above components.
  • a first aspect of the present disclosure provides an agent comprising an organopolysiloxane unit; And, it provides a composition for forming an artificial skin film comprising a nanoparticle coated with a hydrophobic material and a second agent comprising a platinum catalyst supported on the nanoparticles.
  • the nanoparticles that can be used in the composition for forming an artificial skin film may be porous, or may have a wide surface area by having a bend, irregularities, or holes on the surface, but may not be limited thereto. have.
  • the porous nanoparticles may support a platinum-based catalyst, and may form an artificial skin membrane by hydrogen siliconization with an organopolysiloxane unit by the platinum-based catalyst, but may not be limited thereto. .
  • nanoparticles that can be used in the composition for forming an artificial skin film may be harmless to the human body, but may not be limited thereto.
  • the nanoparticles that can be used in the composition for forming an artificial skin film may be porous and harmless to the human body, but may not be limited thereto.
  • the surface area that can be adsorbed becomes wider, so that the number of adsorption of platinum catalyst per nanoparticle increases, resulting in the formation of an artificial skin membrane using a small concentration of nanoparticles. It may be, but may not be limited thereto.
  • the platinum catalyst may be adsorbed on the surface of the nanoparticles coated with the hydrophobic material, but may not be limited thereto.
  • the nanoparticles coated with the hydrophobic material may adsorb the platinum catalyst by hydrophobic-hydrophobic interaction, but may not be limited thereto.
  • the nanoparticles coated with the hydrophobic material may represent a superhydrophobic surface, but may not be limited thereto.
  • the super water-repellent surface is a surface having a very weak bonding force with water, and may represent a surface at which a contact angle with water becomes 150 ° or more.
  • Representative organisms having a natural superhydrophobic surface include, for example, lotus leaves, taro leaves, wings and legs of insects, and have self-cleaning and waterproofing ability to easily remove external contaminants without special work.
  • the composition for forming an artificial skin film may be viscous, but may not be limited thereto.
  • the hydrophobic material is polydimethylsiloxane, gelatin, polyethylene glycol, hydroxypropylmethyl cellulose, methyl cellulose, polyvinylpyrrolidone, starch, ethyl cellulose, alginate, carboxymethyl cellulose, gum arabic , Trigacanth rubber, and combinations thereof may be included, but may not be limited thereto.
  • the nanoparticles by coating the nanoparticles with the hydrophobic material, it is possible to reduce the amount of catalyst of the platinum catalyst, or to achieve a faster reactivity to accelerate the hydrogen siliconization crosslinking reaction, but is not limited thereto. You may not.
  • the nanoparticles may be biocompatible nanoparticles or biodegradable nanoparticles, but may not be limited thereto.
  • the biocompatible material may mean a material that is not toxic to the human body, is chemically inert and has no immunogenicity
  • the biodegradable material may mean a material that can be decomposed by body fluids or microorganisms in a living body. However, this may not be limited.
  • the biocompatible nanoparticles or biodegradable nanoparticles for example, polyethylene glycol, polylactic acid, polyglycolic acid, chitosan, gelatin, collagen, manan, dextransulfate, alpha-cyclodextrin , Beta-cyclodextrin, gamma-cyclodextrin, fructooligosaccharide, isomaltoligosaccharide, inulin, hyaluronic acid, alginate, glycogen, amylose, carboxy, carboxymethyldextran, beta glucan, hydroxyethyl cellulose, carboxymethyl cellulose, fucoidan , Chondroitin, sodium hyaluronate, lactose, DW-EGF, polyester, polyhydroxyalkanoate, poly ( ⁇ -hydroxyacid), poly ( ⁇ -hydroxyacid), poly (3-hydro formula Butyrate-co-valorate; PHBV), poly (3-hydroxypropionate; PHP),
  • the nanoparticles may include, but not limited to, those selected from the group consisting of silica, titanium oxide, zinc oxide, and combinations thereof.
  • the titanium oxide may effectively block ultraviolet rays through absorption, scattering, or reflection in a broad wavelength region, for example, a wavelength in the range of about 280 nm to about 400 nm, cosmetic composition In use, but may indicate a more natural feeling, but may not be limited thereto.
  • the titanium oxide is physically very stable, has a high refractive index, and a small particle size, and thus excellent in chemical properties such as whiteness, hiding power, coloring power, and thus, even when applied to the skin, only the skin is applied to the cosmetic composition. It may have a sunscreen effect, but may not be limited thereto.
  • the dispersion force may be reduced, but may not be limited thereto.
  • a hydrophobic material on the titanium oxide can reduce the cohesive force to increase the dispersibility, but may not be limited thereto.
  • nanoparticles when the nanoparticles exhibit hydrophilicity, adsorption does not occur well after the reaction with the platinum catalyst exhibiting hydrophobicity, separation may appear, but may not be limited thereto.
  • the titanium oxide coated with the hydrophobic material may exhibit a hydrophobic property, and thus may support a platinum catalyst having hydrophobic properties, but may not be limited thereto.
  • the hydrophobic coating method may be performed through deposition, but may not be limited thereto.
  • a liquid or gel-like organic polymer is placed in a reaction vessel, the nanoparticles are placed in a layered structure with a separator in a net form therebetween, and then the organic polymer is deposited on the nanoparticles by vapor phase by heating.
  • the organic polymer is deposited on the nanoparticles by vapor phase by heating.
  • a hydrophobic film but may not be limited thereto.
  • the hydrophobic nanoparticles loaded with the platinum catalyst may maintain the activity of the catalyst, may be stored for a long time, but may not be limited thereto.
  • the hydrophobic nanoparticles loaded with the platinum catalyst may alleviate the toxicity of skin or cells, but may not be limited thereto.
  • mixing the first agent comprising the organopolysiloxane unit and the second agent comprising the hydrophobic nanoparticles loaded with the catalyst to form a thin artificial skin film in minutes. Accordingly, the activity of the platinum catalyst can be maintained, and since the platinum catalyst comes out of the mixed solution after the first agent and the second agent are mixed, the catalyst is not directly exposed to the skin, thereby minimizing skin or cytotoxicity. However, this may not be limited.
  • the platinum catalyst is a platinum carbonyl cyclovinylmethylsiloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethylsiloxane complex, platinum octanealdehyde / octanol complex, and combinations thereof It may be to include one selected from the group consisting of, but may not be limited thereto.
  • the platinum catalyst may be Karlstedt's catalyst, but may not be limited thereto.
  • the content (% by weight) of the platinum may range from about 0.05% to about 10% based on the total weight of the second agent, but may not be limited thereto.
  • the content (% by weight) of platinum may be about 0.05% to about 10%, about 0.05% to about 8%, about 0.05% to about 6%, and about 0.05% to the total weight of the second agent.
  • an appropriate solvent may be used to adsorb the platinum catalyst to the nanoparticles coated with the hydrophobic material.
  • the second agent may be prepared by mixing the solution containing the nanoparticles coated with a hydrophobic material and the solution containing the platinum catalyst and then ultrasonic reaction, but is not limited thereto. have.
  • the ultrasonic response is about 1 minute to about 10 hours, about 1 minute to about 5 hours, about 1 minute to about 4 hours, about 1 minute to about 1 hour, about 1 minute to about 40 minutes, about 1 Minutes to about 30 minutes, about 30 minutes to about 10 hours, about 30 minutes to about 5 hours, about 30 minutes to about 4 hours, about 30 minutes to about 1 hour, or about 5 minutes to about 30 minutes It may be, but may not be limited thereto.
  • the preparation process of the second agent may further include, for about 1 minute to about 1 hour at room temperature for adsorption of the platinum catalyst to the nanoparticles after the ultrasonic reaction.
  • this may not be limited.
  • the solvent of the solution containing the platinum catalyst may include water, alcohol, or an organic solvent, but may not be limited thereto.
  • the organic solvent may be one selected from the group consisting of methanol, ethanol, isopropanol, n-hexane, chloroform, cyclohexane, ether, dichloromethane, benzene, ethyl acetate, and combinations thereof. However, this may not be limited.
  • the solvent of the solution containing the platinum catalyst is an organic solvent exhibiting a non-polar
  • the hydrophobic-hydrophobic interaction between the platinum catalyst and the nanoparticles mixed in the solvent may not be well However, this may not be limited.
  • the solvent content of the solution containing the platinum catalyst may range from about 50% to 90%, but may not be limited thereto.
  • the solvent is ethanol
  • nanoparticles coated with the hydrophobic material may not be mixed well with hydrophilic solvent in less than about 50% ethanol, and the platinum catalyst is completely dissolved in more than about 90% ethanol. May not be adsorbed by the nanoparticles, but may not be limited thereto.
  • nanoparticles coated with a hydrophobic material may further include a functional protein or drug, but may not be limited thereto.
  • the functional protein or drug may be additionally included to be adsorbed or synthesized, but may not be limited thereto.
  • the drug is a chemical drug, protein medicine, peptide medicine, gene therapy nucleic acid molecule, anti-inflammatory, analgesic, anti-arthritis, antispasmodic, antidepressant, antipsychotic, neurostable, anti-anxiety, drug Antagonists, antiparkin disease drugs, cholinergic agonists, anticancer agents, antiangiogenic agents, immunosuppressants, antiviral agents, antibiotics, appetite suppressants, analgesics, anticholinergic agents, antihistamines, antimigraine, hormones, coronary vessels, cerebrovascular or Peripheral vasodilators, contraceptives, antithrombotics, diuretics, antihypertensives, cardiovascular diseases, cosmetic ingredients (e.g., wrinkle improvement agents, skin aging inhibitors and skin whitening agents), and combinations thereof. It may be, but may not be limited thereto.
  • the drug may be a protein medicine, a peptide medicine, or a vitamin containing, but may not be limited thereto.
  • the protein / peptide medicament includes insulin, insulin-like growth factor 1 (IGF-1), growth hormone, erythropoietin, granulocyte-colony stimulating factors (G-CSFs), and GM-CSFs (granulocytes).
  • macrophage-colony stimulating factors interferon alpha, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, epidermal growth factors (EGGFs), calcitonin ), Adrenocorticotropic hormone (ACTH), tumor necrosis factor (TNF), atobisban, buserelin, cetrorelix, deslorelin, desmopressin ), Dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRH-II), gonadore Gonadorelin, goserelin, hystrelin, leuprorelin, leiprenin ( lypressin, octreotide, oxytocin, phytocin, pitressin, secretin, sincalide, terlipressin, thymopen
  • the functional protein is etanercept (etanercept), epoetin alpha (epoetin alpha), infliximab, interferon beta (interferon alpha), insulin lispro (insulin) lispro, filgrastim, imiglucerase, glatiramer acetate, rituximab, pegfilgrastim, insulin grastim, Adalimumab, trastuzumab, bevacizumab, ranibizumab, insulin, growth hormone, tumor necrosis factor-alpha , Interleukin-7, insulin-like growth factor 2, interferon gamma, interferon alpha, interleukin-2, bone formation protein ( osteogenic protein), recombinant plasminogen activator (Recombinant plasminogen-activator), Bone morphogenetic protein 2, antifungal peptide, tissue plasminogen activator, immunoglobulin G, erythemab, erythemlact
  • the second aspect of the present application provides a kit for forming an artificial skin film, comprising the composition for forming an artificial skin film according to the first aspect of the present application.
  • kits for forming the artificial skin film according to the second aspect of the present application With respect to the kit for forming the artificial skin film according to the second aspect of the present application, detailed descriptions of portions overlapping with the first aspect of the present application have been omitted, but the contents described in the first aspect of the present application may be The same can be applied to the second aspect.
  • the third aspect of the present application is applied to the skin by applying a first agent comprising an organopolysiloxane unit, and a second agent comprising nanoparticles coated with a hydrophobic material and a platinum catalyst supported on the nanoparticles to the skin
  • a synthetic agent comprising a polysiloxane polymer is prepared by applying a second agent comprising a nanoparticle coated with a hydrophobic material and a platinum catalyst supported on the nanoparticle, and applying a first agent including an organopolysiloxane unit to the skin.
  • a method for manufacturing an artificial skin film comprising forming a skin film.
  • the second agent may be prepared by mixing the solution containing the nanoparticles coated with the hydrophobic material and the solution containing the platinum catalyst and then ultrasonic reaction, but is not limited thereto. Can be.
  • the ultrasonic response is about 1 minute to about 10 hours, about 1 minute to about 5 hours, about 1 minute to about 4 hours, about 1 minute to about 1 hour, about 1 minute to about 40 minutes, about 1 Minutes to about 30 minutes, about 30 minutes to about 10 hours, about 30 minutes to about 5 hours, about 30 minutes to about 4 hours, about 30 minutes to about 1 hour, or about 5 minutes to about 30 minutes It may be, but may not be limited thereto.
  • the preparation process of the second agent may further include, for about 1 minute to about 1 hour at room temperature for adsorption of the platinum catalyst to the nanoparticles after the ultrasonic reaction.
  • this may not be limited.
  • the nanoparticles may be porous, or have a curved surface, irregularities, or holes on the surface to have a wide surface area, but may not be limited thereto.
  • the porous nanoparticles may support a platinum-based catalyst, and may form an artificial skin membrane by hydrogen siliconization with an organopolysiloxane unit by the platinum-based catalyst, but may not be limited thereto. .
  • the nanoparticles may be harmless to the human body, but may not be limited thereto.
  • the nanoparticles are porous, may be harmless to the human body, but may not be limited thereto.
  • the surface area that can be adsorbed becomes wider, so that the number of adsorption of platinum catalyst per nanoparticle increases, resulting in the formation of an artificial skin membrane using a small concentration of nanoparticles. It may be, but may not be limited thereto.
  • the platinum catalyst may be adsorbed on the surface of the nanoparticles coated with the hydrophobic material, but may not be limited thereto.
  • the nanoparticles coated with the hydrophobic material may adsorb the platinum catalyst by hydrophobic-hydrophobic interaction, but may not be limited thereto.
  • the nanoparticles coated with the hydrophobic material may represent a superhydrophobic surface, but may not be limited thereto.
  • the super water-repellent surface is a surface having a very weak bonding force with water, and may represent a surface at which a contact angle with water becomes 150 ° or more.
  • Representative organisms having a natural superhydrophobic surface include, for example, lotus leaves, taro leaves, wings and legs of insects, and have self-cleaning and waterproofing ability to easily remove external contaminants without special work.
  • the hydrophobic material is polydimethylsiloxane, gelatin, polyethylene glycol, hydroxypropylmethyl cellulose, methyl cellulose, polyvinylpyrrolidone, starch, ethyl cellulose, alginate, carboxymethyl cellulose, gum arabic , Trigacanth rubber, and combinations thereof may be included, but may not be limited thereto.
  • the nanoparticles by coating the nanoparticles with the hydrophobic material, it is possible to reduce the amount of catalyst of the platinum catalyst, or to achieve a faster reactivity to accelerate the hydrogen siliconization crosslinking reaction, but is not limited thereto. You may not.
  • the nanoparticles may be biocompatible nanoparticles or biodegradable nanoparticles, but may not be limited thereto.
  • the biocompatible material may mean a material that is not toxic to the human body, is chemically inert and has no immunogenicity
  • the biodegradable material may mean a material that can be decomposed by body fluids or microorganisms in a living body. However, this may not be limited.
  • the biocompatible nanoparticles or biodegradable nanoparticles for example, polyethylene glycol, polylactic acid, polyglycolic acid, chitosan, gelatin, collagen, manan, dextransulfate, alpha-cyclodextrin , Beta-cyclodextrin, gamma-cyclodextrin, fructooligosaccharide, isomaltoligosaccharide, inulin, hyaluronic acid, alginate, glycogen, amylose, carboxy, carboxymethyldextran, beta glucan, hydroxyethyl cellulose, carboxymethyl cellulose, fucoidan , Chondroitin, sodium hyaluronate, lactose, DW-EGF, polyester, polyhydroxyalkanoate, poly ( ⁇ -hydroxyacid), poly ( ⁇ -hydroxyacid), poly (3-hydro formula Butyrate-co-valorate; PHBV), poly (3-hydroxypropionate; PHP),
  • the nanoparticles may include, but not limited to, those selected from the group consisting of silica, titanium oxide, zinc oxide, and combinations thereof.
  • the titanium oxide may effectively block ultraviolet rays through absorption, scattering, or reflection in a broad wavelength region, for example, a wavelength in the range of about 280 nm to about 400 nm, cosmetic composition In use, but may indicate a more natural feeling, but may not be limited thereto.
  • the titanium oxide is physically very stable, has a high refractive index, and a small particle size, and thus excellent in chemical properties such as whiteness, hiding power, coloring power, and thus, even when applied to the skin, only the skin is applied to the cosmetic composition. It may have a sunscreen effect, but may not be limited thereto.
  • the dispersion force may be reduced, but may not be limited thereto.
  • a hydrophobic material on the titanium oxide can reduce the cohesive force to increase the dispersibility, but may not be limited thereto.
  • nanoparticles when the nanoparticles exhibit hydrophilicity, adsorption does not occur well after the reaction with the platinum catalyst exhibiting hydrophobicity, separation may appear, but may not be limited thereto.
  • the titanium oxide coated with the hydrophobic material may exhibit a hydrophobic property, and thus may support a platinum catalyst having hydrophobic properties, but may not be limited thereto.
  • the hydrophobic coating method may be performed through deposition, but may not be limited thereto.
  • a liquid or gel-like organic polymer is placed in a reaction vessel, the nanoparticles are placed in a layered structure with a separator in a net form therebetween, and then the organic polymer is deposited on the nanoparticles by vapor phase by heating. It may be to form a film, but may not be limited thereto.
  • the hydrophobic nanoparticles loaded with the platinum catalyst may maintain the activity of the catalyst, may be stored for a long time, but may not be limited thereto.
  • the hydrophobic nanoparticles loaded with the platinum catalyst may alleviate the toxicity of skin or cells, but may not be limited thereto.
  • mixing the first agent comprising the organopolysiloxane unit and the second agent comprising the hydrophobic nanoparticles loaded with the catalyst to form a thin artificial skin film in minutes. Accordingly, the activity of the platinum catalyst can be maintained, and since the platinum catalyst comes out of the mixed solution after the first agent and the second agent are mixed, the catalyst is not directly exposed to the skin, thereby minimizing skin or cytotoxicity. However, this may not be limited.
  • the platinum catalyst is a platinum carbonyl cyclovinylmethylsiloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethylsiloxane complex, platinum octanealdehyde / octanol complex, and combinations thereof It may be to include one selected from the group consisting of, but may not be limited thereto.
  • the platinum catalyst may be Karlstedt's catalyst, but may not be limited thereto.
  • the content (% by weight) of the platinum may range from about 0.05% to about 10% based on the total weight of the second agent, but may not be limited thereto.
  • the content (% by weight) of platinum may be about 0.05% to about 10%, about 0.05% to about 8%, about 0.05% to about 6%, and about 0.05% to the total weight of the second agent.
  • an appropriate solvent may be used to adsorb the platinum catalyst to the nanoparticles coated with the hydrophobic material.
  • the second agent may be prepared by mixing the solution containing the nanoparticles coated with a hydrophobic material and the solution containing the platinum catalyst and then ultrasonic reaction, but is not limited thereto. have.
  • the solvent of the solution containing the platinum catalyst may include water, alcohol, or an organic solvent, but may not be limited thereto.
  • the organic solvent may be one selected from the group consisting of methanol, ethanol, isopropanol, n-hexane, chloroform, cyclohexane, ether, dichloromethane, benzene, ethyl acetate, and combinations thereof. However, this may not be limited.
  • the solvent of the solution containing the platinum catalyst is an organic solvent exhibiting a non-polar
  • the hydrophobic-hydrophobic interaction between the platinum catalyst and the nanoparticles mixed in the solvent may not be well However, this may not be limited.
  • the solvent content of the solution containing the platinum catalyst may range from about 50% to 90%, but may not be limited thereto.
  • the solvent is ethanol
  • nanoparticles coated with the hydrophobic material may not be mixed well with hydrophilic solvent in less than about 50% ethanol, and the platinum catalyst is completely dissolved in more than about 90% ethanol. May not be adsorbed by the nanoparticles, but may not be limited thereto.
  • the viscosity of the solution containing the platinum catalyst may range from about 200 to about 1,000 Cs, but may not be limited thereto.
  • the nanoparticles coated with the hydrophobic material may further include a functional protein or drug, but may not be limited thereto.
  • the functional protein or drug may be additionally included to be adsorbed or synthesized, but may not be limited thereto.
  • the drug is a chemical drug, protein medicine, peptide medicine, gene therapy nucleic acid molecule, anti-inflammatory, analgesic, anti-arthritis, antispasmodic, antidepressant, antipsychotic, neurostable, anti-anxiety, drug Antagonists, antiparkin disease drugs, cholinergic agonists, anticancer agents, antiangiogenic agents, immunosuppressants, antiviral agents, antibiotics, appetite suppressants, analgesics, anticholinergic agents, antihistamines, antimigraine, hormones, coronary vessels, cerebrovascular or Peripheral vasodilators, contraceptives, antithrombotics, diuretics, antihypertensives, cardiovascular diseases, cosmetic ingredients (e.g., wrinkle improvement agents, skin aging inhibitors and skin whitening agents), and combinations thereof. It may be, but may not be limited thereto.
  • the drug may be a protein medicine, a peptide medicine, or a vitamin containing, but may not be limited thereto.
  • the protein / peptide medicament includes insulin, insulin-like growth factor 1 (IGF-1), growth hormone, erythropoietin, granulocyte-colony stimulating factors (G-CSFs), and GM-CSFs (granulocytes).
  • macrophage-colony stimulating factors interferon alpha, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, epidermal growth factors (EGGFs), calcitonin ), Adrenocorticotropic hormone (ACTH), tumor necrosis factor (TNF), atobisban, buserelin, cetrorelix, deslorelin, desmopressin ), Dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRH-II), gonadore Gonadorelin, goserelin, hystrelin, leuprorelin, leiprenin ( lypressin, octreotide, oxytocin, phytocin, pitressin, secretin, sincalide, terlipressin, thymopen
  • the functional protein is etanercept (etanercept), epoetin alpha (epoetin alpha), infliximab, interferon beta (interferon alpha), insulin lispro (insulin) lispro, filgrastim, imiglucerase, glatiramer acetate, rituximab, pegfilgrastim, insulin grastim, Adalimumab, trastuzumab, bevacizumab, ranibizumab, insulin, growth hormone, tumor necrosis factor-alpha , Interleukin-7, insulin-like growth factor 2, interferon gamma, interferon alpha, interleukin-2, bone formation protein ( osteogenic protein), recombinant plasminogen activator (Recombinant plasminogen-activator), Bone morphogenetic protein 2, antifungal peptide, tissue plasminogen activator, immunoglobulin G, erythemab, erythemlact
  • the content of the platinum catalyst with respect to the total weight of the second agent may range from about 0.05% to about 20%, but may not be limited thereto.
  • the content of the platinum catalyst is about 0.05% to about 20%, about 0.05% to about 18%, about 0.05% to about 16%, about 0.05% to about 14%, about 0.05% to about 12%, About 0.05% to about 10%, about 0.05% to about 5%, about 0.05% to about 2%, about 0.05% to about 1%, about 0.05% to about 0.1%, about 0.1% to about 20%, about 0.1 % To about 18%, about 0.1% to about 16%, about 0.1% to about 14%, about 0.1% to about 12%, about 0.1% to about 10%, about 0.1% to about 5%, about 0.1% to About 2%, about 0.1% to about 1%, about 1% to about 20%, about 1% to about 16%, about 1% to about 12%, about 1% to about 10%, about 1% to about 5 %, About 5%
  • a nanoparticle coated with a hydrophobic surface and a platinum-based catalyst are prepared and weighed.
  • the platinum catalyst may include a Karlstedt catalyst, the content of which may be 2% based on the total weight of the second agent, and the viscosity of the Karlstedt catalyst in solution may be about 200 cS. This may not be limited.
  • the viscosity of the solution of the Karlstedt catalyst in the form of a solution that can be used as the platinum catalyst may have a variety of values of the commercially available Karlstedt catalyst, various commercially available Karlstedt catalysts can be selected and used appropriately.
  • the nanoparticles coated with the hydrophobic material are dispersed in a solvent and then washed. The dispersion may be performed by ultrasonic waves, but may not be limited thereto.
  • the platinum catalyst is mixed and dispersed in a solvent.
  • the dispersion may be performed through the ultrasonic waves as described above, but may not be limited thereto.
  • the dispersed platinum catalyst and the nanoparticles coated with the hydrophobic material are mixed and mixed by an ultrasonic reaction to support the platinum catalyst on the nanoparticles coated with the hydrophobic material.
  • the nanoparticles coated with the hydrophobic material may carry a functional protein or drug together, but may not be limited thereto.
  • the nanoparticles loaded with the platinum catalyst are centrifuged to remove and wash the supernatant to obtain two agents, and the two agents are mixed with one agent containing organopolysiloxane units to form an artificial skin membrane.
  • compositions for forming artificial skin membranes (1)
  • Part 1 Ingredient Composition and Preparation
  • 1st is An agent comprising organopolysiloxane units, which is composed of a silicone phase and an aqueous phase.
  • an aqueous phase of the above put the samples shown in Table 1 in a 300 mL bottle, then mixed for 15 minutes at 350 rpm using a homogenizer, and then increase the step by step 450 rpm, 550 Mix for 15 minutes at rpm. Thereafter, the samples shown in Table 1 below were prepared in another 300 mL bottle for preparation of the first silicone phase, followed by mixing at 650 rpm for 15 minutes using a homogenizer. Then, the aqueous solution phase was poured slowly onto the silicon being mixed.
  • Part 2 Ingredient Composition and Preparation
  • the second agent is a preparation on which a platinum catalyst is supported and is composed of a silicon phase and an aqueous solution phase.
  • aqueous phase in order to prepare an aqueous phase, first, the samples shown in Table 2 were put in a 300 mL bottle, and then mixed at a 280 rpm for 10 minutes using a homogenizer.
  • the silicon phase samples shown in Table 2 below were placed in another 300 mL bottle, and mixed for 10 minutes at 650 rpm using a homogenizer. Then, the aqueous phase was poured slowly on the said silicon being mixed. Next, the mixed solution was mixed for 5 minutes at 680 rpm using a homogenizer. After mixing, 2% Pt was added according to the ratio shown in Table 2 below, followed by mixing at 700 rpm for 5 minutes using a homogenizer to obtain a second agent.
  • compositions for forming an artificial skin film (2)
  • Part 1 Ingredient Composition and Preparation
  • aqueous phase consisting of a silicone phase and an aqueous phase
  • a first aqueous phase consisting of a silicone phase and an aqueous phase
  • step rpm The mixture was raised to 450 rpm and 550 rpm for 15 minutes each.
  • the samples shown in Table 3 below were put in another 300 mL bottle for preparation of the first silicone phase, and mixed for 15 minutes at 650 rpm using a homogenizer.
  • the aqueous phase was poured slowly onto the silicon being mixed. After mixing the mixed solution at 650 rpm for 10 minutes using a homogenizer, 27% of fumed silica was added and then mixed again for 5 minutes. 10 N sodium hydroxide was added to the mixed solution, followed by mixing for 5 minutes at 650 rpm using a homogenizer to obtain a first agent.
  • Part 2 Ingredient Composition and Preparation
  • the second agent is a preparation on which a platinum catalyst is supported and is formed of a silicon phase and an aqueous solution phase.
  • a platinum catalyst in order to prepare an aqueous phase, the samples shown in Table 4 were placed in a 300 mL bottle, followed by mixing at 280 rpm for 10 minutes using a homogenizer. Then, the silicon phase samples shown in Table 4 below were prepared in a second 300 mL bottle for the preparation of the second silicone phase, and then mixed at 650 rpm for 10 minutes using a homogenizer. After slowly pouring the aqueous solution onto the silicone, the mixture was mixed at 680 rpm for 5 minutes using a homogenizer. 2% platinum catalyst was added to the mixed solution according to the ratio shown in Table 4, followed by mixing at 700 rpm for 5 minutes using a homogenizer to obtain a second agent.
  • the washed silica nanoparticles were transferred to a vessel containing the platinum catalyst to have a total volume of 6 mL.
  • the silica nanoparticles and the platinum catalyst were stirred and mixed, and then reacted for 20 minutes using an ultrasonic reactor, and then left at room temperature for 1 hour. Thereafter, the reaction sample was centrifuged at 10000 rpm for 10 minutes and the supernatant was removed and washed twice. After washing, the sample was dried and then prepared by mixing a second emulsion with a composition excluding the catalyst. After the first agent prepared above was applied to the skin, a second agent emulsion was applied thereon to form an artificial skin membrane.
  • the titanium oxide nanoparticles and the platinum catalyst were stirred and mixed, and then reacted for 20 minutes using an ultrasonic reactor, and then left at room temperature for 1 hour. After the reaction, the sample was centrifuged at 10000 rpm for 10 minutes, and the supernatant was removed and washed twice. After washing, the sample was dried and mixed in a second emulsion. After the first agent prepared above was applied to the skin, a second agent emulsion containing hydrophobic coated nanoparticles onto which a platinum catalyst was adsorbed was applied thereon to form an artificial skin film.
  • FIG. 4 is a photograph comparing measured and contact angles of hydrophilic silica nanoparticles (left) and hydrophobic silica nanoparticles (right), which are coated with PDMS and have been treated with PDMS without surface treatment
  • FIG. It is a photograph comparing and measuring the contact angle of the hydrophilic titanium oxide nanoparticles (left) and the titanium oxide nanoparticles (right) showing hydrophobicity by coating with PDMS.
  • the contact angle cannot be measured because most of the water is absorbed, whereas in the case of nanoparticles coated with a hydrophobic material, the contact angle is 150 ° or more, which has superhydrophobic properties. You can see that.
  • FIG. 6 is a photograph of (a) uncoated silica nanoparticles (hydrophilic) and hydrophobic silica nanoparticles coated with PDMS, respectively, mixed with a platinum catalyst and (b) a photograph after centrifugation of (a).
  • the hydrophilic silica nanoparticles are not adsorbed after the reaction with the hydrophobic platinum catalyst, and thus the platinum catalyst is not adsorbed onto the particles and is separated from the silica particles.
  • silica nanoparticles coated with a hydrophobic material and having superhydrophobic properties can be confirmed that the platinum catalyst is adsorbed by hydrophobic-hydrophobic interaction.
  • FIG. 7 is a photograph of artificial skin film formation using only (a) platinum catalyst and (b) artificial skin film formation using nanoparticles to which platinum catalyst is adsorbed.
  • 8A to 8D are graphs showing the difference in surface potential before and after adsorption of a platinum catalyst using zeta-potential.
  • the zeta potential is changed as the platinum catalyst is adsorbed in this embodiment.
  • the reaction time passes over 4 hours, the zeta potential is very low, and it can be confirmed that the stability is lowered. Therefore, the reaction time of 1 hour was confirmed as the maximum reaction time and the experiment was conducted using the reaction time within 1 hour.
  • the adsorption rate according to the ultrasonic reaction time when the platinum catalyst and the nanoparticles were mixed was measured.
  • FIG. 9 shows results of optimization experiments on adsorption conditions of hydrophobic silica nanoparticles and a platinum catalyst.
  • a platinum catalyst at a concentration of 1% was used for adsorption experiments on 2% mass of silica by volume of solvent.
  • the control sample without sonication showed a 50% adsorption rate compared to the control, and immediately after sonication for 20 minutes (0 minutes), adsorption after 20 minutes, 40 minutes, 1 hour, and 4 hours. The rates were compared respectively.
  • the concentration analysis of the platinum catalyst was analyzed using ICP-OES. As a result of the experiment, it was confirmed that the adsorption rate was the highest when the ultrasonic reaction was performed for 20 minutes and then left at room temperature for 20 minutes.
  • the platinum catalyst alone and the silica nanoparticles which adsorbed the platinum catalyst were respectively After dispersion in the solvent at concentrations of 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, and 5%, the platinum concentration at each concentration was analyzed by ICP-OES.
  • Adsorption of the platinum catalyst to the nanoparticles was measured at a higher concentration at most concentrations than at the control using only the platinum catalyst without the nanoparticles, and the concentration of the catalyst was 2% or more (nanoparticle concentration: 2%). In one case, the catalyst was no longer adsorbed to the nanoparticles, and the concentration tended to decrease (FIG. 10). The above results indicate that as the concentration of the platinum catalyst increases, the catalysts aggregate together, so that the dispersion is not well performed in the ethanol solvent. However, when the platinum catalyst is adsorbed on the nanoparticles, it is more dispersed in the solvent. Inferred.
  • Lactate dehydrogenase (LDH) analysis was performed to compare the toxicity of platinum catalyst alone and silica nanoparticles adsorbed platinum catalyst (FIG. 11).
  • a 96-well assay plate containing cells in cell culture was prepared. Thereafter, test compounds and vehicle controls were placed in appropriate wells and the cells were incubated at a temperature of 37 ° C. with a final volume of 100 ⁇ l to 150 ⁇ l.
  • a maximum LDH release control was made using a Lysis solution. 10 ⁇ lysis solution (per 100 ⁇ l original volume) was added to positive control wells 45 minutes prior to adding assay reagent. Samples of all wells were taken 50 ⁇ l and transferred to a new 96-well flat clear bottom plate. 50 ⁇ l of the reaction reagent was added to each well, and wrapped in a foil or an opaque box and incubated at room temperature for 30 minutes while protected from light. After incubation, the stop solution was added to each well to terminate the reaction. Bubbles formed in the wells were removed using a syringe needle, and the absorbance was measured at 490 nm or 492 nm within 1 hour after the stop solution treatment.
  • the result value was obtained by subtracting the average value of the cell culture background from the experimental value of each well, and then using the following formula for calculating the cytotoxicity (percent cytotoxicity).
  • the primary skin irritation test (primary patch test) of the composition for forming an artificial skin film prepared in the above embodiments was performed.
  • the concentration of the artificial skin film forming composition used was the same as in Examples 2-1, 2-2, and the sample names are shown in Table 5 below.
  • the subjects were based on 33 healthy men and women between 20 and 55 years of age, and a total of 4 times (24 days after patch removal, 24 hours after patch removal, 48 hours after patch removal) were evaluated for skin irritation.
  • Example # 1 the composition 1 agent for artificial skin film formation
  • sample # 2 the composition 2 agent for artificial skin film formation
  • sample # 3 was 35 mg of van der Bend chamber (Van der Bend). , Brielle, the Netherlands) and fixed on the test site.
  • the patch was applied to the skin for 24 hours, and after removal, the area was marked with a marking pen and observed after 30 minutes, 24 hours, and 48 hours, respectively.
  • the skin primary irritation test result determination table reflecting the stimulation classification criteria of the Environmental Protection Agency (EPA) Standard Evaluation Procedure Dermal Classification System ( The stimulus group was determined according to Table 7).
  • Mean Irritation Index (Sum of 3 irritation scores of each volunteer) / (Number of volunteers ⁇ 3)
  • Table 8 shows the experimental results of the subjects who completed the skin irritation evaluation experiment.
  • the average skin irritation degree of the composition 1 for artificial skin film formation was 0.11 and was determined to be non-irritating according to the above criteria.
  • the average skin irritation degree of the composition 2 for artificial skin film formation was 0.04 and also non-irritating. It became. Even when the composition 1 and agent 2 for artificial skin film formation were mixed, the average skin irritation was 0.14, which was determined to be non-irritating.
  • Sample name (sample control number) Constellation #One Artificial skin film cream (one set, S-S002) Cream #2 Artificial skin cream (2 products, S-S003) Cream
  • test subjects were based on those with 20 eyes of 30-55 years old healthy females with wrinkles around the eyes corresponding to a photodamage score of 2-6.
  • One week before the start of the experiment the use of treatments, cosmetics, quasi-drugs, and medical treatments and massages for the purpose of skin improvement that could affect the evaluation results were prohibited.
  • the experiment was carried out a total of three times (before sample application, immediately after sample application, and after 3 hours of sample application).
  • the average roughness (Ra) is the average of the absolute values of the lengths from the center line to the cross-sectional curve of the surface when the center line is drawn at the roughness height of the cross section
  • Rmax Maximum roughness depth Represents the difference between the highest acid and the lowest valley within a single measurement range.
  • the temporary eye wrinkle coverage by PRIMOS High Resolution was calculated using the following formula.
  • the paired t-test confirmed the significance between the sample application and the sample application at the 95% confidence interval.
  • Statistical analysis program used IBM SPSS Statistics 21.0 (SPSS, Chicago, IL, USA).
  • the Ra value decreased 9.926% immediately after application to a statistically significant level (p ⁇ 0.01) compared to before application, and the Rmax value was lower than before application.
  • Statistically significant level (p ⁇ 0.01) decreased by 8.784% immediately after application.
  • the subjects were based on those with 20 eyes of 30 to 55 years old healthy females with wrinkles around the eyes corresponding to the optical damage score of 2 to 6.
  • One week before the start of the experiment the use of treatments, cosmetics, quasi-drugs, and medical treatments and massages for the purpose of skin improvement that could affect the evaluation results were prohibited.
  • the experiment was carried out a total of three times (before sample application, immediately after sample application, and after 3 hours of sample application).
  • the first cream of the composition for artificial skin film formation is reduced by the size of a bean pill and evenly spread on the folds of the eye area, which is the designated sample application site, and then the second cream is applied in the same amount as the first agent
  • the sample was allowed to dry for 3 to 5 minutes after being applied to the same site.
  • ElleadSys Pro is an integrated image processor for consistently managing the shooting environment, conditions, analysis and record keeping of images.
  • Ellead ColorMap consists of 40 color patches by adding 14 kinds of skin tone references to 26 standard colors. By using the device to implement the skin color of the various images taken with the digital device closest to the actual skin color can improve the accuracy and reliability of the image analysis. All images of the sustainability experiment were analyzed after applying ElleadSys Pro.
  • Percentage Percentage (Measurement immediately after sample application-measured 3 hours after sample application) / (Measured value immediately after sample application-measured value before sample application) ⁇ 100
  • Table 12 shows the results of the standard deviation measurement of S (Saturation) using facial imaging and image analysis software using VISIA-CR, the results of the statistical analysis in Table 13, and the results of the persistence in Table 14 (Fig. 15). And FIG. 16).
  • the sample application area and the non-application area were reduced statistically significant level (p ⁇ 0.001) immediately after application. Indicated.
  • the standard deviation value of S of the sample application site did not show a statistically significant level difference after 3 hours of application compared to immediately after the sample application (Table 12 and Table 13).
  • the sample application site had a sustained rate of 43.149% and there was no statistically significant difference between the sample application site and the non-application site (Table 14).
  • the Ra value was reduced by 9.926% immediately after application to a statistically significant level (p ⁇ 0.01).
  • Rmax value decreased 8.784% immediately after application to a statistically significant level (p ⁇ 0.01) compared to before application. Therefore, the composition for artificial skin film formation (first agent, S-S002) and the composition for artificial skin film formation (second agent, S-S003) are judged to help temporary eye wrinkle cover immediately after application.
  • composition for artificial skin film formation (part 1, S-S002) and the composition for artificial skin film formation (part 2, S-S003) help to sustain makeup skin uniformity after 3 hours of application.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition pour la formation d'une couche de peau artificielle à l'aide de nanoparticules hydrophobes, et un procédé de préparation d'une couche de peau artificielle utilisant la composition pour la formation d'une couche de peau artificielle.
PCT/KR2018/010627 2018-01-30 2018-09-11 Composition pour la formation d'une couche de peau artificielle à l'aide de nanoparticules hydrophobes, et procédé de préparation d'une couche de peau artificielle l'utilisant WO2019151602A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0011367 2018-01-30
KR20180011367 2018-01-30

Publications (1)

Publication Number Publication Date
WO2019151602A1 true WO2019151602A1 (fr) 2019-08-08

Family

ID=67479987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/010627 WO2019151602A1 (fr) 2018-01-30 2018-09-11 Composition pour la formation d'une couche de peau artificielle à l'aide de nanoparticules hydrophobes, et procédé de préparation d'une couche de peau artificielle l'utilisant

Country Status (2)

Country Link
KR (1) KR20190092226A (fr)
WO (1) WO2019151602A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102289840B1 (ko) * 2020-11-25 2021-08-18 주식회사 메가코스 반응성 실리콘을 포함하는 화장료 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130058702A (ko) * 2010-04-30 2013-06-04 다우 코닝 도레이 캄파니 리미티드 오가노폴리실록산 및 이들의 계면활성제, 분말 처리제, 오일­기재 원료의 증점제 또는 겔화제로서의 용도, 겔 및 에멀젼 조성물, 그리고 이를 포함하는 외용 제제 및 화장품
KR20130135843A (ko) * 2010-08-31 2013-12-11 리빙 프루프 인코포레이티드 피부 조성물 및 이의 사용방법
KR20140116888A (ko) * 2011-12-27 2014-10-06 다우 코닝 도레이 캄파니 리미티드 신규한 액상 오르가노폴리실록산 및 이의 용도
KR20150007808A (ko) * 2013-07-12 2015-01-21 인하대학교 산학협력단 나노섬유 및 나노입자를 포함하는 인공피부 및 충전제용 복합지지체, 및 이의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130058702A (ko) * 2010-04-30 2013-06-04 다우 코닝 도레이 캄파니 리미티드 오가노폴리실록산 및 이들의 계면활성제, 분말 처리제, 오일­기재 원료의 증점제 또는 겔화제로서의 용도, 겔 및 에멀젼 조성물, 그리고 이를 포함하는 외용 제제 및 화장품
KR20130135843A (ko) * 2010-08-31 2013-12-11 리빙 프루프 인코포레이티드 피부 조성물 및 이의 사용방법
KR20140116888A (ko) * 2011-12-27 2014-10-06 다우 코닝 도레이 캄파니 리미티드 신규한 액상 오르가노폴리실록산 및 이의 용도
KR20150007808A (ko) * 2013-07-12 2015-01-21 인하대학교 산학협력단 나노섬유 및 나노입자를 포함하는 인공피부 및 충전제용 복합지지체, 및 이의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU , BETTY ET AL.: "An elastic second skin", NATURE MATERIALS, vol. 15, no. 8, 2016, pages 1 - 47, XP055584497, doi:10.1038/nmat4635 *

Also Published As

Publication number Publication date
KR20190092226A (ko) 2019-08-07

Similar Documents

Publication Publication Date Title
KR102592682B1 (ko) 피부 위의 적용을 위한 조성물 및 방법
KR101935060B1 (ko) 피부 조성물 및 이의 사용방법
KR101148013B1 (ko) 국소용 제제, 및 활성제를 기재로 전달하는 방법
DE60221069T2 (de) Polyethersiloxancopolymernetzwerk-Zusammensetzung und Emulsionen diese enthaltend
US7935364B2 (en) Patterned gradient wound dressing and methods of using same to promote wound healing
WO2016167527A1 (fr) Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci
WO2010079978A2 (fr) Composition utilisable pour le traitement de l'inflammation faisant appel à des antigènes abh
KR19990023719A (ko) 건선 치료용 매니큐어액
WO2019151602A1 (fr) Composition pour la formation d'une couche de peau artificielle à l'aide de nanoparticules hydrophobes, et procédé de préparation d'une couche de peau artificielle l'utilisant
Gönül et al. Effect of EGF dosage forms on alkali burned corneal wound healing of mice
KR101895038B1 (ko) 스피큘을 포함하는 용해성 필름 및 이의 용도
CN108778239A (zh) 组合物和制备方法
Anderegg et al. Collagen/glycosaminoglycan-based matrices for controlling skin cell responses
WO2016099159A1 (fr) Microstructure microcellulaire et son procédé de fabrication
CN106580740A (zh) 一种用于皮肤除皱、美容、修饰的透明聚合物薄膜及其使用方法
Izykowska et al. Effect of melatonin on human keratinocytes and fibroblasts subjected to UVA and UVB radiation in vitro
WO2017065508A1 (fr) Composition cosmétique comprenant des particules de gommage solubles dans l'eau contenant un polypeptide et/ou une culture cellulaire
Lee et al. Wound healing effects of paste type acellular dermal matrix subcutaneous injection
WO2017090974A1 (fr) Composition cosmétique en émulsion contenant un agent inorganique bloquant le rayonnement uv et son procédé de préparation
Janahmadi et al. Enhancing rat full-thickness skin wounds with a mixed aloe/chitosan gel
WO2024090820A1 (fr) Composition de gel pour recouvrir une plaie et son procédé de fabrication
KR102360819B1 (ko) 유화 분리 방지 화장료 조성물, 이를 함침시킨 담체 및 이를 포함하는 화장품
KR100770117B1 (ko) 주름개선용 피부외용제 조성물
CN111012943A (zh) 一种含有侧柏叶提取液的快速成膜液体创可贴
WO2019098736A1 (fr) Composition d'emballage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18903806

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18903806

Country of ref document: EP

Kind code of ref document: A1